Phase 1 Breast Cancer Trial, Recruiting NCT07081555 Sponsor: Affibody Condition: Breast Cancer
Back to Breast Cancer

Phase 1 Breast Cancer Trial, Recruiting

NCT07081555
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have breast cancer that cannot be surgically removed and has either spread to nearby areas or to other parts of the body
  • People whose breast cancer has been confirmed by a tissue or cell sample showing a specific protein called HER2 at high levels (tested within the last 2 years), meeting one of two specific measurement thresholds (confirm with trial site)
  • People who have at least one tumour that is 15mm or larger in size
  • People who are reasonably able to carry out daily activities, rated on a standard medical scale as a 2 or below out of 4 (confirm with trial site)

For Part A of the trial only:

  • People who are currently receiving, or are about to start, a standard anti-cancer treatment

For Part B of the trial only:

  • People whose cancer has been confirmed by scans to have gotten worse within the last three months
  • People who have already received at least 3 different lines of standard anti-cancer treatment for advanced disease
  • People who have finished their most recent anti-cancer treatment and whose side effects from that treatment have mostly resolved (confirm with trial site)

Who may not be able to join:

  • People who have active cancer spread to the brain
  • People who have recently received another experimental treatment drug within a certain time window before the trial (confirm with trial site for exact timeframes)
  • People who have received any anti-cancer treatment, including radiation therapy within the last 7 days, since their most recent documented cancer progression

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 46859883800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Affibody
Registry
ClinicalTrials.gov
Start date
6 October 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Treatment emergent adverse events; Dose Limiting Toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov